Kimberly-Clark is laying down $40bn to buy Kenvue in a massive deal that has puzzled some investors, as the maker of Tylenol struggles with weak sales, lawsuits and White House attacks linking its painkiller to autism.
Shares of Kimberly-Clark dropped sharply after the Monday announcement as stockholders scrutinised the 46 percent premium being paid for the former Johnson &, Johnson unit that has had a turbulent year.
Recommended Stories
list of 4 itemsend of list
Kenvue ousted its CEO in July, and has been under fire from United States President Donald Trump over unproven claims that Tylenol use during pregnancy can cause autism in children.
Kenvue shares, which had dropped sharply since Trump’s comments, jumped 17.5 percent on Monday. Many investors have been awaiting a sale of all or parts of the company for months, following activist pressure.
Jay Woods, chief market strategist at Freedom Capital Markets, said the market reaction suggests , some investors , believe Kimberly-Clark “may be buying damaged goods”.
Despite the concerns, Kimberly-Clark forecast $2.1bn in annual cost savings from the deal, with the addition of Kenvue’s vast portfolio of brands from Listerine mouthwash to skincare names like Aveeno and Neutrogena expected to bring in annual revenues of roughly $32bn for the combined company.
“Both companies sit side by side on store shelves, so the scale and distribution logic make sense even if the Tylenol overhang remains a shadow any buyer would rather avoid”, said Kimberly Forrest, chief investment officer at Bokeh Capital Partners.
Tylenol headaches
“Kimberly-Clark will take on potential litigation risk for the Tylenol brand… This is hard to quantify”, said TD Cowen analyst Robert Moskow.
There are concerns around , Kenvue’s , potential legal exposure to hundreds of private lawsuits alleging the company hid supposed links between Tylenol and autism or attention deficit hyperactivity disorder in children.
While US Health and Human Services Secretary Robert F Kennedy Jr recently said there is no conclusive evidence of such a link, he called existing data “very suggestive”.
US sales of Tylenol fell 11 percent between September 20 and October 4 after Trump’s remarks, BNP Paribas analyst Navann Ty said in a note last month.
Kenvue is also battling litigation tied to its talc-based baby powder products.
“Most investors expected Kenvue to sell off select brands, not the entire company, given the Tylenol and talc overhangs. But Kimberly-Clark likely saw long-term value in a strong brand portfolio trading at a steep discount”, said James Harlow, senior vice president at Novare Capital Management.
‘ Awesome ‘ for Kenvue
Kenvue , investors , cheered the deal.
One long-term investor who has spoken with the board and management over the past few months called the deal “awesome,” while others claimed that the price was not as good as they had anticipated before the White House’s administration began to criticize the business.
Kenvue has long experienced investor activism and weakness in its core businesses, particularly those that deal with skin health and beauty. The skin health segment’s third-quarter sales decreased by 3.2 percent to $ 1.04 billion, according to the company’s statement on Monday.
Kirk Perry, who was earlier named CEO of Kenvue, said, “We’re living in the murky middle, which is no place to live right now.
Conflicts in the sector
Kimberly-Clark is also navigating a more value-seeking shopper-driven consumer goods environment, which is compelled by businesses like Procter &, Gamble, to invest in smaller pack sizes and reduce underperforming business units.
As part of a restructuring, It  announced on Monday that it had sold a majority stake in its international tissue business to Brazilian pulp producer Suzano. The company said on Monday that the sale will help the Kenvue buyout.
Still, some analysts believe it reflects a shifting business climate. This demonstrates how large, transformational mergers are being fueled by easing rate expectations, according to Bokeh Capital’s and Forrest’s.
acquiring more than $40 billion
For each Kenvue share held, shareholders will receive $ 3.50 per share and $ 0.15 Kimberly-Clark shares. That implies an estimated $40.32 billion in equity, according to Reuters news agency calculations.
The agreement, which is anticipated to close in the second half of 2026, will be financed primarily by using debt and cash, with JPMorgan Chase Bank providing the commitment.
If the deal fails, either party may be required to pay a cash termination fee of $1.2 billion, according to a regulatory filing.